Insider Trading Alert - VLGEA, ASFI And BSX Traded By Insiders

Yesterday, Jan. 11, 2016, 33 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $203.00 to $32,000,000.00.

Highlighted Stocks Traded by Insiders:

Village Super Market (VLGEA) - FREE Research Report

Estate of Perry Sumas, who is Shareholder at Village Super Market, sold 5,558 shares at $25.42 on Jan. 11, 2016. Following this transaction, the Shareholder owned 748,425 shares meaning that the stake was reduced by 0.74% with the 5,558-share transaction.

The shares most recently traded at $24.93, down $0.49, or 1.98% since the insider transaction. Historical insider transactions for Village Super Market go as follows:

  • 4-Week # shares sold: 11,315
  • 12-Week # shares sold: 59,414
  • 24-Week # shares sold: 149,647

The average volume for Village Super Market has been 25,700 shares per day over the past 30 days. Village Super Market has a market cap of $245.0 million and is part of the services sector and retail industry. Shares are down 5.31% year-to-date as of the close of trading on Monday.

Village Super Market, Inc. operates a chain of supermarkets in the United States. Its stores feature specialty departments, such as onsite bakery, an expanded delicatessen, natural and organic foods, ethnic and international foods, prepared foods, and pharmacies. The stock currently has a dividend yield of 4.01%. The company has a P/E ratio of 11.3. Currently, there are no analysts who rate Village Super Market a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VLGEA - FREE

TheStreet Quant Ratings rates Village Super Market as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, attractive valuation levels and good cash flow from operations. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Village Super Market Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Asta Funding (ASFI) - FREE Research Report

Mangrove Partners Master Fund, Ltd., who is 10% Owner at Asta Funding, bought 2,800 shares at $7.73 on Jan. 11, 2016. Following this transaction, the 10% Owner owned 1.5 million shares meaning that the stake was boosted by 0.19% with the 2,800-share transaction.

The shares most recently traded at $7.82, up $0.09, or 1.1% since the insider transaction. Historical insider transactions for Asta Funding go as follows:

  • 4-Week # shares bought: 53,958
  • 12-Week # shares bought: 98,308
  • 12-Week # shares sold: 7,000
  • 24-Week # shares bought: 98,308
  • 24-Week # shares sold: 7,000

The average volume for Asta Funding has been 16,900 shares per day over the past 30 days. Asta Funding has a market cap of $96.4 million and is part of the services sector and diversified services industry. Shares are down 2.64% year-to-date as of the close of trading on Monday.

Asta Funding, Inc., together with its subsidiaries, engages in consumer receivable business in the United States. The company operates through four segments: Consumer Receivables, Personal Injury Claims, Structured Settlements, and GAR Disability Advocacy. The company has a P/E ratio of 53.3. Currently, there are no analysts who rate Asta Funding a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ASFI - FREE

TheStreet Quant Ratings rates Asta Funding as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and weak operating cash flow. Get the full Asta Funding Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Boston Scientific (BSX) - FREE Research Report

Pratt Timothy A., who is EVP, GC & Chief Admin Officer at Boston Scientific, sold 7,160 shares at $17.67 on Jan. 11, 2016. Following this transaction, the EVP, GC & Chief Admin Officer owned 303,776 shares meaning that the stake was reduced by 2.3% with the 7,160-share transaction.

The shares most recently traded at $17.58, down $0.09, or 0.54% since the insider transaction. Historical insider transactions for Boston Scientific go as follows:

  • 4-Week # shares bought: 11,700
  • 4-Week # shares sold: 45,126
  • 12-Week # shares bought: 11,700
  • 12-Week # shares sold: 240,405
  • 24-Week # shares bought: 11,700
  • 24-Week # shares sold: 247,318

The average volume for Boston Scientific has been 8.9 million shares per day over the past 30 days. Boston Scientific has a market cap of $23.4 billion and is part of the health care sector and health services industry. Shares are down 7.1% year-to-date as of the close of trading on Monday.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. Currently, there are 14 analysts who rate Boston Scientific a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSX - FREE

TheStreet Quant Ratings rates Boston Scientific as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Boston Scientific Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Dow Turns Higher as Microsoft Gives Stocks a Boost

Dow Turns Higher as Microsoft Gives Stocks a Boost

Microsoft Hits Record High as Cloud Sales Drive Q4 Earnings Blowout

Microsoft Hits Record High as Cloud Sales Drive Q4 Earnings Blowout

How to Trade General Electric's Stock After Earnings for Superior Gains

How to Trade General Electric's Stock After Earnings for Superior Gains

FAANG and the Fed: Trump's Rate Hike Concern Could Add to Tech Performance

FAANG and the Fed: Trump's Rate Hike Concern Could Add to Tech Performance

Top Strategist Reveals the Stocks to Focus On For the Last Half of 2018

Top Strategist Reveals the Stocks to Focus On For the Last Half of 2018